2-octynoic acid-BSA
Based on 1 Customer Validation
NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research.
For research use only. We do not sell to patients.
- Purity: 97.09%
- Molecular Weight:69068 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
2-octynoic acid (20 min (0°C stirring); overnight (ambient temp warming); 3 h (BSA coupling)) is successfully conjugated to BSA via lysine residues following a multi-step chemical synthesis and purification workflow[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 8 to 9 weeks of age, immunization-induced PBC-like autoimmune cholangitis)[1]
-
Dosage:100 μg per mouse
-
Administration:i.p.; initial in Complete Freund’s Adjuvant, boosts every 2 weeks in Incomplete Freund’s Adjuvant; up to 24 weeks
-
Result:Induced PDC-E2-reactive antibodies in 100% (13/13) of immunized mice by 8 weeks post-immunization.
Elevated serum IgG (OD: 0.33) and IgM (OD: 0.08) anti-PDC-E2 levels at 4 weeks post-immunization.
Elevated serum IgG (OD: 1.23), IgA (OD: 0.55), and IgM (OD: 0.27) anti-PDC-E2 levels at 8 weeks post-immunization.
Elevated serum TNF-α (79.0 pg/mL) and IFN-γ (14.7 pg/mL) levels at 4 weeks post-immunization, with elevation sustained through 12 weeks.
Caused mild portal lymphoid cell infiltrates, mild chronic nonsuppurative destructive cholangitis-like bile duct lesions, ductopenia, scattered epithelioid granulomas, and small areas of mild focal necrosis in all tested mice at 12 and 24 weeks post-immunization.
Decreased liver CD4/CD8 ratio to 2.03 at 12 weeks post-immunization compared to controls.
Increased total liver lymphoid cell number to at 12 weeks post-immunization.
Increased absolute numbers of liver CD8+ T cells and CD19+ B cells at 12 weeks post-immunization.
Increased frequency of liver CD8+ T cells co-expressing CD44 at 12 weeks post-immunization.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 69068 (average)
-
Color Colorless to light yellow
-
SMILES
[2-octynoic acid-BSA]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2-octynoic acid-BSA Related Classifications
HY-160719 Related Classifications
Powered by Bioz